All updated as on -
The size of the global leukapheresis market, which was estimated to be worth $245.9 million in 2022, is anticipated to increase to $561.9 million by 2030, rising at a CAGR of 9.6% between 2023 and 2030. A laboratory method called leukapheresis is used to remove white blood cells from a sample of blood. It can be used for research, to remove autologous or allogeneic blood cells for later transplantation into the patient, to lower an excessively high white blood cell count, or both.
One of the key elements accelerating the market's growth and demand is the rising incidence and prevalence of leukemia. Additionally, over the forecast period of 2023 to 2030, the market is expected to grow as a result of the high demand for leukopaks in clinical research, rising blood donation rates, technological advancements, and rising demand and adoption of leukopaks in numerous applications, such as R&D activities. Additionally, the increased approvals for the method of isolating White Blood Corpuscles (WBC) for R&D activities, coupled with rising investments by major players in research activities, are also boosting the market expansion. The market is likely to see significant development potential due to the expanding economies and rising investments from pharma-biotech firms, academic institutions, and top players.
White blood cells (leukocytes) are separated and collected from a patient's blood during a procedure called leukapheresis. White blood cells are normally isolated and removed using specialized apheresis units that use centrifugation or filtering methods. Leukocyte collection for research, the creation of cellular therapies, the treatment of certain blood conditions, and the prevention of cancer are some of the uses for leukapheresis that are most common in the fields of hematology and oncology. As part of therapeutic operations, the recovered leukocytes can be further processed, altered, or injected back into the patient.
Leukopaks are enriched leukapheresis products made of different blood cells, such as lymphocytes, monocytes, and dendritic cells, and are extracted from peripheral blood. A good source of different immune cells is leukopaks. The main driver of demand for leukopaks is the requirement for human cells in all forms of oncology, immunotherapy, and cell biology research. On the other hand, businesses in the pharmaceutical and biotechnology industries have put more of an emphasis on creating immunotherapies based on cells, like the CAR-T therapy for leukemia. Utilizing T-cells purified from leukopaks, CAR-T treatment creates chimeric antigen receptor T-cells by genetic modification. About 300 pharmaceutical companies are working on CAR-T therapy research and development. As of August 2023, 316 CAR T-cell-related studies were active in the US, according to ClinicalTrials.gov. Six CAR T cell treatments have been authorized as of April 2023, demonstrating previously unheard-of success in patients with multiple myeloma and B-cell malignancies. However, CAR T cell therapy faces significant obstacles from side effects include immune effector cell-associated neurotoxicity and cytokine release syndrome.
Therapeutic leukapheresis can result in a number of problems, including those brought on by a low WBC count and the potential for harmful interactions with anticoagulant medications. The venipuncture site may also be uncomfortable, painful, red, and bruised. Patients who undergo the surgery run the risk of experiencing brief vertigo and losing consciousness. Leukapheresis operations account for a sizable portion of cases of hypocalcemia, or low calcium levels. In these circumstances, it is advised to slow down the process, reduce the anticoagulation, and administer calcium supplements orally or intravenously. Furthermore, there have been reports of modest RBC or platelet loss. WBCs are separated by apheresis devices, and the remaining blood is then given back to the patient in accordance with various manufacturer settings that could affect the level of hemoglobin or hematocrit. For donors who have a history of anemia and thrombocytopenia, this could pose serious complications.
Due to a variety of variables, including a developed healthcare infrastructure, an increasing number of leukemia patients, and a rising number of R&D activities, North America has dominated the leukapheresis market. Additionally, efforts to improve cancer patients through the use of CAR T cells in conjunction with established key market players engaged in new product launches, strategic partnerships, mergers and acquisitions, and expansions are projected to support market growth.
Report Coverage
Global Leukapheresis research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Leukapheresis report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Leukapheresis competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Leukapheresis market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Leukapheresis market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Leukapheresis market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Asahi Kasei Medical Co. Ltd (Japan), Haemonetics Corporation (U.S.), TERUMO BCT INC. (U.S.), STEMCELL Technologies Inc. (Canada), Fresenius SE & Co. KGaA (Germany), HemaCare (U.S.), B. Braun Melsungen AG (Germany), Caltag Medsystems Limited (U.K.), AllCells (U.S.), StemExpress (U.S.), Precision for Medicine, Inc. (U.S.), Lonza (Switzerland), BioIVT (U.S.), Lmb Technologie GmbH (Germany), Grifols, S.A (Spain), and Kaneka Pharma Europe NV (U.S.), Charles River Laboratories International, Inc., Adacyte Therapeutics, SB-Kawasumi Laboratories, Inc., Cerus Corporation, ZenBio, Macopharma SA, Miltenyi Biotec, Guangzhou Daji Medical Science, MEDICA S.p.A, PuriBlood Medical Co. Ltd., and Beijing ZKSK Technology Co. Ltd.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Leukapheresis market based on the below-mentioned segments:
Global Leukapheresis Market, By Product
Devices
Disposables
Global Leukapheresis market, By Application
Therapeutic Applications
Research Applications
Global Leukapheresis Market, By End User
Blood Centers
Hospitals
Others
Global Leukapheresis market, Regional Analysis
One of the key elements accelerating the market's growth and demand is the rising incidence and prevalence of leukemia. Additionally, over the forecast period of 2023 to 2030, the market is expected to grow as a result of the high demand for leukopaks in clinical research, rising blood donation rates, technological advancements, and rising demand and adoption of leukopaks in numerous applications, such as R&D activities. Additionally, the increased approvals for the method of isolating White Blood Corpuscles (WBC) for R&D activities, coupled with rising investments by major players in research activities, are also boosting the market expansion. The market is likely to see significant development potential due to the expanding economies and rising investments from pharma-biotech firms, academic institutions, and top players.
White blood cells (leukocytes) are separated and collected from a patient's blood during a procedure called leukapheresis. White blood cells are normally isolated and removed using specialized apheresis units that use centrifugation or filtering methods. Leukocyte collection for research, the creation of cellular therapies, the treatment of certain blood conditions, and the prevention of cancer are some of the uses for leukapheresis that are most common in the fields of hematology and oncology. As part of therapeutic operations, the recovered leukocytes can be further processed, altered, or injected back into the patient.
Leukopaks are enriched leukapheresis products made of different blood cells, such as lymphocytes, monocytes, and dendritic cells, and are extracted from peripheral blood. A good source of different immune cells is leukopaks. The main driver of demand for leukopaks is the requirement for human cells in all forms of oncology, immunotherapy, and cell biology research. On the other hand, businesses in the pharmaceutical and biotechnology industries have put more of an emphasis on creating immunotherapies based on cells, like the CAR-T therapy for leukemia. Utilizing T-cells purified from leukopaks, CAR-T treatment creates chimeric antigen receptor T-cells by genetic modification. About 300 pharmaceutical companies are working on CAR-T therapy research and development. As of August 2023, 316 CAR T-cell-related studies were active in the US, according to ClinicalTrials.gov. Six CAR T cell treatments have been authorized as of April 2023, demonstrating previously unheard-of success in patients with multiple myeloma and B-cell malignancies. However, CAR T cell therapy faces significant obstacles from side effects include immune effector cell-associated neurotoxicity and cytokine release syndrome.
Therapeutic leukapheresis can result in a number of problems, including those brought on by a low WBC count and the potential for harmful interactions with anticoagulant medications. The venipuncture site may also be uncomfortable, painful, red, and bruised. Patients who undergo the surgery run the risk of experiencing brief vertigo and losing consciousness. Leukapheresis operations account for a sizable portion of cases of hypocalcemia, or low calcium levels. In these circumstances, it is advised to slow down the process, reduce the anticoagulation, and administer calcium supplements orally or intravenously. Furthermore, there have been reports of modest RBC or platelet loss. WBCs are separated by apheresis devices, and the remaining blood is then given back to the patient in accordance with various manufacturer settings that could affect the level of hemoglobin or hematocrit. For donors who have a history of anemia and thrombocytopenia, this could pose serious complications.
Due to a variety of variables, including a developed healthcare infrastructure, an increasing number of leukemia patients, and a rising number of R&D activities, North America has dominated the leukapheresis market. Additionally, efforts to improve cancer patients through the use of CAR T cells in conjunction with established key market players engaged in new product launches, strategic partnerships, mergers and acquisitions, and expansions are projected to support market growth.
Report Coverage
Global Leukapheresis research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Leukapheresis report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Leukapheresis competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Leukapheresis market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Asahi Kasei Medical Co. Ltd (Japan), Haemonetics Corporation (U.S.), TERUMO BCT INC. (U.S.), STEMCELL Technologies Inc. (Canada), Fresenius SE & Co. KGaA (Germany), HemaCare (U.S.), B. Braun Melsungen AG (Germany), Caltag Medsystems Limited (U.K.), AllCells (U.S.), StemExpress (U.S.), Precision for Medicine, Inc. (U.S.), Lonza (Switzerland), BioIVT (U.S.), Lmb Technologie GmbH (Germany), Grifols, S.A (Spain), and Kaneka Pharma Europe NV (U.S.), Charles River Laboratories International, Inc., Adacyte Therapeutics, SB-Kawasumi Laboratories, Inc., Cerus Corporation, ZenBio, Macopharma SA, Miltenyi Biotec, Guangzhou Daji Medical Science, MEDICA S.p.A, PuriBlood Medical Co. Ltd., and Beijing ZKSK Technology Co. Ltd. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Leukapheresis Market from 2021 to 2030.
- Market Forecast for Leukapheresis Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Leukapheresis competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Leukapheresis
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Leukapheresis market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Leukapheresis market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Asahi Kasei Medical Co. Ltd (Japan), Haemonetics Corporation (U.S.), TERUMO BCT INC. (U.S.), STEMCELL Technologies Inc. (Canada), Fresenius SE & Co. KGaA (Germany), HemaCare (U.S.), B. Braun Melsungen AG (Germany), Caltag Medsystems Limited (U.K.), AllCells (U.S.), StemExpress (U.S.), Precision for Medicine, Inc. (U.S.), Lonza (Switzerland), BioIVT (U.S.), Lmb Technologie GmbH (Germany), Grifols, S.A (Spain), and Kaneka Pharma Europe NV (U.S.), Charles River Laboratories International, Inc., Adacyte Therapeutics, SB-Kawasumi Laboratories, Inc., Cerus Corporation, ZenBio, Macopharma SA, Miltenyi Biotec, Guangzhou Daji Medical Science, MEDICA S.p.A, PuriBlood Medical Co. Ltd., and Beijing ZKSK Technology Co. Ltd.
Primary Target Market
- Market Players of Leukapheresis
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Leukapheresis market based on the below-mentioned segments:
Global Leukapheresis Market, By Product
Devices
Disposables
Global Leukapheresis market, By Application
Therapeutic Applications
Research Applications
Global Leukapheresis Market, By End User
Blood Centers
Hospitals
Others
Global Leukapheresis market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive leukapheresis market market research and competitor analysis for your business to help you develop more profound insights into the leukapheresis market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the leukapheresis market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.